020839 S-015
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER(S)

NDA 20-839/S-015

Trade Name: Plavix Tablets

Generic Name(s): (clopidogrel bisulfate)

Sponsor: Sanofi-Synthelabo, Inc.

Agent:

Approval Date: June 18, 2001

Indication: Provides for CBE manufacturing controls
NDA 20-839/S-015

Sanofi-Synthelabo, Inc.
Attention: John Purpura
90 Park Avenue
New York, NY 10016

Dear Mr. Purpura:

Please refer to your supplemental new drug application dated December 15, 2000, received December 18, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Plavix (clopidogrel bisulfate) Tablets, 75 mg.

This "Changes Being Effected in 30 days" supplemental new drug application provides for ε

We have completed the review of this supplemental application, and it is approved. Please note, for future, reference that Є process for clopidogrel bisulfate. According to the Guidance for Industry, Changes to an Approved NDA or ANDA, any process change made after the Є in drug substance manufacture should be submitted in a prior approval supplement.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Colleen LoCicero, RPh, Regulatory Health Project Manager, at (301) 594-5332.

Sincerely,

[See appendix, electronic signature page]

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I for the
Division of Cardio-Renal Drug Products, (HFD-110)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kasturi Srinivasachar
6/18/01 05:15:55 PM
REVIEW OF CHEMISTRY, MANUFACTURING AND CONTROLS
Division of Cardio Renal Drug Products (HFD-110)

1. Chemistry Review # 1

2. NDA # 20-839 S-015 (CBE 30, process change)

3. Name & Address of Applicant
   Sanofi-Synthelabo Inc
   90 Park Avenue
   New York, New York 10016
   (212) 551-4261
   Representative
   John Purpura
   Associate Director CMC
   Drug Regulatory Affairs
   (212) 551-4261

4. Supplement S-015

5. Proprietary Name: Plavix Tablets

6. Nonproprietary Name: Clopidogrel bisulfate

7. Code Name: SR 25990C

8. Chemical Type / Submission Priority: N/A

9. Supplement provides for 
   The amount of: —— is reduced from: ———— This represents a—— reduction in the quantity of: ——— of the synthesis.

10. Previous Documents: None

11. Submissions Reviewed:
    (a) CBE Supplement dated December 15, 2000 that refers to data in DMF——
    (b) DMF—— resubmitted November 30, 2000
    (c) Type II DMF——

12. Pharmacological Category: Prevention of vascular ischemia

13. Rx / OTC: Rx

14. Dosage Form: Tablet (film coated) TCM

15. Strength / Potency: Equivalent to 75 mg base

16. Route of Administration: oral

17. Spots: NO

18. Chemical Name: Methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetate sulfate (1:1)
   CAS # 120202-66-6 C₃₆H₄₁ClNO₅S - H₂SO₄ MWt base 321.83 MWt salt 419.9
Related / Supporting Documents:
(a) Type II DMF \( \text{drug} \) resubmitted in its entirety on 11/30/00. (pages 118-134, 182-196, 221-227, 242-245, 301-304 and 316-318)
(b) Type II DMF \( \text{drug} \) substance: Sanofi–Synthelabo may obtain drug substance according to description of the entire synthesis of \( \text{drug} \) substance in their DMF.

Evaluation of DMF Status: Acceptable. According to Jim Short’s DMF Review (Sept 15, 1997), you may manufacture all the \( \text{drug} \) substance, (clopidogrel bisulfate \( \text{for Plavix Tablets described in NDA 20839. The processes for making them are the same for} \) \( \text{drug} \) substance. -- The last Annual Update of DMF \( \text{is dated July 27, 1998. There are no significant CMC changes that require a formal review in the update.} \)

Status of Consults and Other Reviews: Verification of CGMP Compliance is not required for this process change. \( \text{is a FDA approved manufacturer of} \) \( \text{drug} \) substance at present. Additional verification of CGMP Compliance is not required now.

Comments:
(a) DMF \( \text{that describes the synthesis of clopidogrel bisulfate is terminated.} \)
(b) Previous versions of DMF \( \text{submitted Mar. 31, 2000 and Sept 18, 2000 are terminated.} \)
(c) DMF \( \text{(resubmission dated November 2000) contains the updated description of the entire synthesis of the drug substance.} \)
(d) The comparison of impurity profiles of \( \text{in the DMF (resubmission dated November 2000) page 225.} \)
(e) The comparison of analytical data for drug substance clopidogrel bisulfate \( \text{made from the} \) \( \text{is in the DMF (resubmission dated November 2000) pages 301 to 304.} \)
(f) All specifications are met. No specifications are changed
(g) NDA 20-839 was approved November 17, 1997

Conclusions and Recommendation:
(a) The letter to the applicant should state that \( \text{I recommend approval of the supplement.} \)
(b) Based on CMC Review (#2) dated June 13, 2001 of the Nov 2000 amendment to DMF \( \text{I recommend approval of the supplement.} \)

Reviewer: Florian Zielinski
Date Completed: June 18, 2001
Distribution
Original NDA 20-839/S-015
HFD-110/Division File
HFD-110/Project Manager, Locicero
HFD-110/F Zielinski
Initiated by K Srinivasachar

File Name: NDA 20839 S-015 new process.doc
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
______________________________
Florian Zielinski
6/18/01 11:19:27 AM
CHEMIST

Kasturi Srinivasachar
6/18/01 05:08:58 PM
CHEMIST